Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib Neoadjuvant in ALK+ NSCLC (NEOLORA)
NCT06682884Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Nov 2024
- Primary completion
- Apr 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by Peking University People's Hospital. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06682884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06682884.